CCEL

Cryo-Cell International, Inc. (CCEL) - 10-Q Summary

Business Context and Reporting Period

This summary covers the quarterly report (Form 10-Q) for Cryo-Cell International, Inc. for the period ended May 31, 2026. The Company operates in three segments: private cord blood and tissue storage, manufacturing of PrepaCyte CB processing units, and public cord blood banking. The Company is headquartered in Oldsmar, Florida, with storage facilities in Durham, North Carolina.

Key Financial Metrics

Revenue Breakdown (Six Months 2026): Processing and storage fees accounted for $15.36 million (99% of total revenue). Public banking revenue was $47,895, and product revenue was $52,776.

Material Changes vs. Prior Period

• Revenue Decline: Total revenue decreased by approximately 2.8% year-over-year. This was driven by a 14% decrease in new domestic cord blood specimens processed, partially offset by a 3% increase in recurring annual storage fees.
• Public Banking Volatility: Public cord blood banking revenue dropped significantly from $124,767 in the prior year to $47,895, attributed to volatility in customer demand.
• Expense Management: Cost of sales decreased by 13% to $3.33 million. However, Selling, General, and Administrative (SG&A) expenses increased by 8% to $9.63 million.
• Debt Reduction: The Company repaid a significant portion of its revolving line of credit. The line of credit balance was $2.3 million as of November 30, 2025, and was fully repaid ($0 balance) as of May 31, 2026.
• Profitability: Net income decreased slightly to $601,694 compared to $638,640 in the prior period, despite improved operating cash flow.

Outlook, Risks, and Contingencies

• Duke University Arbitration: The Company is engaged in a material legal dispute with Duke University regarding a Patent and Technology License Agreement. Cryo-Cell alleges fraudulent inducement and breach of contract, seeking damages exceeding $100 million. Duke has terminated the agreement and filed counterclaims. A final hearing is scheduled for late July 2026.
• Strategic Pause: Due to the Duke dispute, the Company has paused the opening of the Cryo-Cell Institute for Cellular Therapies and placed the proposed spinoff of its subsidiary, Celle Corp., on hold. The Company does not anticipate further investment in Duke-related activities until the dispute is resolved.
• Listing Compliance: The Company received notice from NYSE American regarding non-compliance with continued listing standards (Section 1003(a)). A compliance plan was accepted on May 6, 2026, granting an extension until September 9, 2027, to regain compliance. Failure to comply could result in delisting.
• Liquidity: Management anticipates that cash, marketable securities, and operating cash flows will be sufficient to fund needs for the next 12 months. However, future capital needs remain uncertain pending the resolution of the Duke arbitration.

Investor Verification Checklist

• Duke Arbitration Outcome: Monitor the July 2026 hearing results, as an unfavorable outcome could materially impact financial position and future growth strategies.
• NYSE American Compliance: Verify progress on the compliance plan to avoid potential delisting, which could affect stock liquidity and price.
• New Enrollment Trends: Assess the 14% decline in new domestic specimens to determine if this is a temporary fluctuation or a structural shift in market demand.
• Debt Covenants: Review the Credit Agreement with Susser Bank to ensure continued compliance with leverage and debt service coverage ratios, especially given the reduction in the revolving credit facility commitment to $8 million.
• Deferred Revenue Recognition: Note the significant deferred revenue balance ($62.8 million) and the timing of its recognition, which impacts future revenue stability.